Recombinant MS4A1 (Ocrelizumab Biosimilar) antibody

Catalog No. ABIN7487883

This Mammalian Cells Monoclonal antibody specifically detects MS4A1 (Ocrelizumab Biosimilar) in ELISA. It exhibits reactivity toward Human.

Quick Overview for Recombinant MS4A1 (Ocrelizumab Biosimilar) antibody (ABIN7487883)

Target: MS4A1 (Ocrelizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This MS4A1 (Ocrelizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-MS4A1 (Ocrelizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb

Characteristics: Antibody Type: IgG1-nd

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for MS4A1 (Ocrelizumab Biosimilar)

Target: MS4A1 (Ocrelizumab Biosimilar)

Target Type: Biosimilar

Background: 2H7
Ocrelizumab is a CD20-directed cytolytic antibody, which is suitable for the treatment of patients with relapsed or primary progressive multiple sclerosis. It is a second-generation recombinant humanized monoclonal antibody of isotype IgG1 that can selectively target B lymphocytes expressing CD20 antigen. Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, which can cause neurological dysfunction. Most patients with MS experience recurrent episodes with functional deterioration, followed by recovery or remission.

CAS-No: 637334-45-3